Tanner Kempton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tanner Kempton has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alec P. Marticoff
Department of Otolaryngology, Head & Neck Surgery, University of Iowa, Iowa City, IA 52242, USA
1 shared publication - Caden Duffy
Department of Otolaryngology, Head & Neck Surgery, University of Iowa, Iowa City, IA 52242, USA
1 shared publication - Douglas M. Bennion
Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, San Diego, CA 92093, USA
1 shared publication - Grant Podhajsky
Department of Otolaryngology, Head & Neck Surgery, University of Iowa, Iowa City, IA 52242, USA
1 shared publication - Kenny Nguyen
Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, AR
1 shared publication - Kiran S. Marla
Department of Otolaryngology, Head & Neck Surgery, University of Iowa, Iowa City, IA 52242, USA
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 743
Repurposing Renin–Angiotensin System Drugs for the Treatment of Audiovestibular Disorders
Audiovestibular disorders arising from the inner ear (e.g., hearing loss, tinnitus, vertigo) are widely prevalent in the United States. Yet, medical treatments targeting the underlying pathology of these disorders remain scarce. The practice of repurposing FDA-approved drugs for new therapeutic indications has become increasingly common, offering a lower risk route to treatment development with fewer barriers to implementation, as safety profiles are already established. The renin–angiotensin system (RAS) is well known for its role in blood pressure and fluid balance, and its overactivation induces acute and chronic inflammation and oxidative stress. This review discusses existing evidence and proposed otoprotective mechanisms of RAS inhibition, specifically using angiotensin II type 1 receptor blockers (ARBs), which support the repurposing of these medications as novel treatments to affect the inner ear pathologies that underlay hearing loss, tinnitus, and vertigo.
- 16 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 743
Open AccessRepurposing Renin–Angiotensin System Drugs for the Treatment of Audiovestibular Disorders
Audiovestibular disorders arising from the inner ear (e.g., hearing loss, tinnitus, vertigo) are widely prevalent in the United States. Yet, medical treatments targeting the underlying pathology of these disorders remain scarce. The practice of repurposing FDA-approved drugs for new therapeutic indications has become increasingly common, offering a lower risk route to treatment development with fewer barriers to implementation, as safety profiles are already established. The renin–angiotensin system (RAS) is well known for its role in blood pressure and fluid balance, and its overactivation induces acute and chronic inflammation and oxidative stress. This review discusses existing evidence and proposed otoprotective mechanisms of RAS inhibition, specifically using angiotensin II type 1 receptor blockers (ARBs), which support the repurposing of these medications as novel treatments to affect the inner ear pathologies that underlay hearing loss, tinnitus, and vertigo.